EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

Amber K Hamilton, Alexander B Radaoui, Matthew Tsang, Daniel Martinez, Karina L Conkrite, Khushbu Patel, Simone Sidoli, Alberto Delaidelli, Apexa Modi, Jo Lynne Rokita, Maria V Lane, Nicholas Hartnett und 26 weitere

Cancer Cell · 2024

DOI: 10.1016/j.ccell.2024.10.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024. Verfasst von Amber K Hamilton und 37 weiteren Autor:innen. Beteiligte Einrichtung: Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Calcium-Binding Proteins, Membrane Proteins, Immunoconjugates. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Cancer Research UK, Cancer Research UK Cambridge Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapies produce remarkable results in B cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor and normal tissues to identify biologically relevant cell surface immunotherapeutic targets for neuroblastoma, an often-fatal childhood cancer. Proteogenomic analyses reveal sixty high-confidence candidate immunotherapeutic targets, and we prioritize delta-like canonical notch ligand 1 (DLK1) for further study. High expression of DLK1 directly correlates with a super-enhancer. Immunofluorescence, flow cytometry, and immunohistochemistry show robust cell surface expression of DLK1. Short hairpin RNA mediated silencing of DLK1 in neuroblastoma cells results in increased cellular differentiation. ADCT-701, a DLK1-targeting antibody-drug conjugate (ADC), shows potent and specific cytotoxicity in DLK1-expressing neuroblastoma xenograft models. Since high DLK1 expression is found in several adult and pediatric cancers, our study demonstrates the utility of a proteogenomic approach and credentials DLK1 as an immunotherapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaCalcium-Binding ProteinsMembrane ProteinsImmunoconjugatesAntineoplastic Agents, ImmunologicalImmunotherapyProteogenomicsCell Line, TumorXenograft Model Antitumor AssaysMice, SCIDHumansFemaleAnimalsMiceKaplan-Meier EstimateBiomarkers, TumorGene Expression Regulation, NeoplasticRNA-SeqChildMolecular Targeted Therapy

Stichwörter der Autor:innen

DLK1antibody-drug conjugatecancerimmunotherapymass spectrometryneuroblastomasurfaceome

Substanzen

DLK1 protein, humanCalcium-Binding ProteinsMembrane ProteinsBiomarkers, TumorImmunoconjugatesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Center for Data-Driven Discovery in Biomedicine and Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Center for Data-Driven Discovery in Biomedicine and Division of Neurosurgery, Children's H…

Förderung

  • NCI NIH HHS
  • Cancer Research UK
  • Cancer Research UK Cambridge Research Institute
  • W W Smith Charitable Trust
  • Alex's Lemonade Stand Foundation for Childhood Cancer
  • The Mark Foundation for Cancer Research
  • National Cancer Institute
  • American Association for Cancer Research

Zitieren

APA

Hamilton, A. K., Radaoui, A. B., Tsang, M., Martinez, D., Conkrite, K. L., Patel, K., Sidoli, S., Delaidelli, A., Modi, A., Rokita, J. L., Lane, M. V., Hartnett, N., Lopez, R. D., Zhang, B., Zhong, C., Ennis, B., Miller, D. P., Brown, M. A., Rathi, K. S., …, & Diskin, S. J. (2024). A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.10.003

Vancouver

Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, et al. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell. 2024. doi:10.1016/j.ccell.2024.10.003

BibTeX
@article{Hamilton2024,
  author = {Hamilton, Amber K and Radaoui, Alexander B and Tsang, Matthew and Martinez, Daniel and Conkrite, Karina L and Patel, Khushbu and Sidoli, Simone and Delaidelli, Alberto and Modi, Apexa and Rokita, Jo Lynne and Lane, Maria V and Hartnett, Nicholas and Lopez, Raphael D and Zhang, Bo and Zhong, Chuwei and Ennis, Brian and Miller, Daniel P and Brown, Miguel A and Rathi, Komal S and Raman, Pichai and Pogoriler, Jennifer and Bhatti, Tricia and Pawel, Bruce and Glisovic-Aplenc, Tina and Teicher, Beverly and Erickson, Stephen W and Earley, Eric J and Bosse, Kristopher R and Sorensen, Poul H and Krytska, Kateryna and Mosse, Yael P and Havenith, Karin E and Zammarchi, Francesca and van Berkel, Patrick H and Smith, Malcolm A and Garcia, Benjamin A and Maris, John M and Diskin, Sharon J},
  title = {A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma},
  journal = {Cancer Cell},
  year = {2024},
  doi = {10.1016/j.ccell.2024.10.003}
}
Kostenlos starten →